Sanfer, a Mexico City, Mexico-based independent pharmaceutical company, received a $500m minority investment from Caisse de dépôt et placement du Québec (CDPQ).
The deal is expected to close later this year, subject to customary regulatory approvals.
The investment will enable Sanfer to execute on its continued expansion plans across Mexico and the broader Latin American region, both organically and through further acquisitions.
Led by Ricardo Amtmann A., Chairman and CEO, Sanfer is a pharmaceutical company with presence in over 25 countries across Latin America. For over 78 years, the company has provided pharmaceutical solutions to physicians and consumers by manufacturing and selling human and animal health products across over ten therapeutic fields.
Over the past two decades, it has closed over 100 brand acquisitions, acquired 8 pharmaceutical companies and launched over 100 new products across Mexico and Latin America.
Existing backer GA will retain a significant minority stake in the company.